Hemophilia A

What is Hemophilia A?

Hemophilia A is a rare inherited bleeding disorder caused by a deficiency or dysfunction of clotting factor VIII, a protein essential for normal blood clotting. This X-linked genetic condition primarily affects males, though females can be carriers and occasionally experience symptoms. With a prevalence of approximately 1 in 5,000-10,000 male births worldwide, hemophilia A accounts for about 80-85% of all hemophilia cases. The condition is classified by the Orphanet rare disease database under code ORPHA:98878.

Key statistics

Symptoms

Common symptoms include excessive bleeding after injury or surgery, spontaneous internal bleeding, easy bruising, prolonged bleeding from cuts, nosebleeds, and bleeding into joints and muscles.

Symptoms vary significantly based on the severity of factor VIII deficiency. **Severe hemophilia A** (less than 1% normal factor VIII activity) presents with spontaneous bleeding episodes, particularly into joints (hemarthroses) causing pain, swelling, and potential permanent damage. Bleeding into muscles can create painful hematomas, while intracranial hemorrhages represent life-threatening emergencies. **Moderate hemophilia A** (1-5% factor VIII activity) typically involves prolonged bleeding after trauma or surgery, with occasional spontaneous bleeding episodes. **Mild hemophilia A** (5-40% factor VIII activity) may only become apparent after significant trauma, dental procedures, or surgery, with patients experiencing unexpectedly prolonged bleeding times. Early symptoms in infants include excessive bleeding from circumcision, unusual bruising patterns, and bleeding into soft tissues during normal developmental activities like crawling.

Causes and risk factors

Hemophilia A results from mutations in the F8 gene located on the X chromosome, which provides instructions for producing factor VIII protein. The X-linked recessive inheritance pattern means affected males pass the condition to all daughters (who become carriers) but no sons. Carrier mothers have a 50% chance of passing the mutation to each child – affected sons will have hemophilia while daughters become carriers.

Submit Your Paper

Risk factors include having a family history of bleeding disorders, particularly on the maternal side. However, approximately 30% of cases result from spontaneous genetic mutations with no family history. Advanced maternal age may slightly increase the risk of new mutations, though this association is less pronounced than in some other genetic conditions.

Prevention

Currently, there is no known way to prevent hemophilia A. However, early detection through genetic screening and carrier testing can help families make informed decisions. Prenatal diagnosis is available through chorionic villus sampling or amniocentesis for families with known mutations. Carrier testing for at-risk females can identify those who might pass the condition to their children. Genetic counseling is strongly recommended for families affected by hemophilia A to understand inheritance patterns, reproductive options, and family planning strategies.

Complications

Without proper treatment, hemophilia A can lead to severe, life-threatening complications. Repeated bleeding into joints (hemophilic arthropathy) causes progressive joint damage, chronic pain, and significant disability. Muscle hematomas can compress nerves and blood vessels, potentially causing compartment syndrome requiring emergency intervention. Intracranial hemorrhages represent the most serious complication, occurring in 2-8% of people with severe hemophilia and carrying high mortality and morbidity rates.

Chronic complications include iron deficiency anemia from repeated blood loss, pseudotumors (blood-filled cysts that can erode bone), and psychological impacts from chronic pain and activity restrictions. Before modern treatment protocols, many patients developed severe joint deformities requiring surgical intervention and resulting in permanent mobility limitations.

Diagnosis

Diagnosis involves comprehensive coagulation studies and factor-specific testing. Initial screening tests include prothrombin time (PT), partial thromboplastin time (PTT), and complete blood count. The PTT is typically prolonged while PT remains normal in hemophilia A. Definitive diagnosis requires factor VIII activity assays, which measure the percentage of normal clotting activity present.

Genetic testing identifies specific mutations in the F8 gene, enabling carrier testing and prenatal diagnosis. Family history assessment helps identify inheritance patterns, though the absence of family history doesn’t rule out hemophilia A due to spontaneous mutations. In severe cases, diagnosis often occurs early in life following excessive bleeding episodes, while mild cases may not be identified until adulthood during pre-surgical testing or after unexplained bleeding events.

Treatment

Treatment focuses on replacing deficient factor VIII through regular infusions and managing bleeding episodes promptly. Factor VIII concentrates remain the cornerstone of therapy, available as plasma-derived or recombinant products. Prophylactic treatment involves regular factor VIII infusions 2-3 times weekly to maintain protective factor levels and prevent spontaneous bleeding.

Desmopressin can be effective in mild hemophilia A by stimulating release of stored factor VIII. Emicizumab, a groundbreaking bispecific monoclonal antibody, mimics factor VIII function and can be administered subcutaneously weekly, offering improved quality of life. Antifibrinolytic agents like tranexamic acid help stabilize clots during dental procedures or minor surgeries.

Gene therapy represents a promising frontier, with several clinical trials showing encouraging results for potentially curative treatments. Comprehensive care includes physical therapy, orthopedic management, and psychosocial support through specialized hemophilia treatment centers.

Prognosis

With modern treatment, people with hemophilia A can expect near-normal life expectancy and quality of life. Early initiation of prophylactic factor VIII therapy significantly reduces bleeding episodes and prevents joint damage. Patients receiving optimal care typically maintain normal joint function and can participate in most activities with appropriate precautions.

Without treatment, severe hemophilia A carries significant mortality risk, particularly from intracranial hemorrhages and severe bleeding episodes. Historical data showed reduced life expectancy and severe disability from joint damage. However, contemporary management has transformed outcomes, with many patients achieving normal educational, professional, and personal milestones when treatment is accessible and consistently maintained.

Quality of life

Living with hemophilia A requires ongoing medical management but need not severely limit daily activities. Regular exercise, particularly swimming and cycling, helps maintain joint health and muscle strength while avoiding high-impact sports that increase bleeding risk. Dietary considerations include maintaining adequate iron intake and avoiding medications that affect platelet function, such as aspirin.

Mental health support addresses anxiety around bleeding episodes and helps develop coping strategies for chronic condition management. Educational accommodations may include modified physical education activities and emergency action plans. Workplace considerations involve ensuring access to factor concentrates and educating colleagues about emergency procedures. Support groups and patient organizations provide valuable peer connections and advocacy resources. Technology improvements, including portable factor concentrates and home infusion training, enable greater independence and travel flexibility.

Pregnancy and fertility

Hemophilia A does not directly affect male fertility, though bleeding complications can impact sexual health. For carrier females, pregnancy generally increases factor VIII levels, often normalizing them during the third trimester. However, postpartum hemorrhage risk remains elevated, requiring specialized obstetric care and factor replacement planning.

Genetic counseling is essential for family planning, with options including prenatal diagnosis, preimplantation genetic testing, and adoption considerations. Carrier females should undergo factor VIII level testing before pregnancy to guide delivery planning. Delivery at specialized centers with hemophilia expertise ensures appropriate management of potential complications. Male infants born to carrier mothers require careful monitoring for bleeding signs and prompt factor level testing.

Children

Pediatric hemophilia A management requires specialized expertise and family-centered care approaches. Early diagnosis is crucial, as severe cases often present within the first two years of life with unusual bleeding patterns. Child-friendly factor concentrates and delivery systems help minimize treatment trauma while ensuring adequate protection.

School accommodations include emergency action plans, modified physical activities, and staff education about bleeding recognition and response. Growth and development typically proceed normally with adequate treatment, though joint bleeding episodes require prompt intervention to prevent long-term damage. Transition planning to adult care begins during adolescence, emphasizing self-management skills and independence. Family support and education help parents balance protective instincts with encouraging normal childhood experiences and development.

When to see a doctor

Seek immediate emergency care for head injuries, severe abdominal pain, persistent vomiting, sudden severe headaches, neck stiffness, or any signs suggesting internal bleeding. Significant trauma, even without obvious external bleeding, requires prompt medical evaluation and likely factor replacement.

Schedule routine care for unusual bruising patterns, prolonged bleeding from minor cuts, joint pain or swelling, and nosebleeds lasting longer than 10-15 minutes. Pre-surgical or dental procedure planning requires coordination with hematology specialists to optimize factor levels and minimize bleeding risks. Regular monitoring appointments help adjust prophylactic regimens and assess for complications.

Regional context

Limited specific data exists regarding hemophilia A prevalence in the Caucasus region, though genetic founder effects in isolated populations can influence local prevalence rates. Healthcare infrastructure development in Georgia, Armenia, and Azerbaijan has improved access to factor concentrates and specialized care, though challenges remain in rural areas. Regional hemophilia societies work to improve treatment access and patient education. GMJ welcomes contributions from regional researchers to build the evidence base for hemophilia A in the Caucasus.

Research and clinical trials

Current research focuses on extended half-life factor VIII products, novel non-factor therapies, and gene therapy approaches. Several gene therapy trials have demonstrated promising results, with some patients achieving sustained factor VIII production following single treatments. Research into subcutaneous factor VIII delivery and alternative dosing strategies aims to improve treatment convenience and adherence.

ClinicalTrials.gov lists numerous ongoing studies investigating new treatments, including next-generation factor VIII products and immune tolerance protocols for patients who develop inhibitory antibodies. Biomarker research seeks to personalize treatment approaches based on individual bleeding patterns and factor pharmacokinetics.

Frequently asked questions

Can people with hemophilia A play sports?

Yes, with proper prophylactic treatment and precautions. Low-impact activities like swimming, golf, and tennis are generally safe, while contact sports require careful risk-benefit assessment and specialized protective equipment.

Will my child with hemophilia A have a normal lifespan?

With modern treatment, children with hemophilia A can expect near-normal life expectancy. Early, consistent treatment prevents most serious complications and allows for typical development and activities.

How is hemophilia A different from hemophilia B?

Both cause similar bleeding symptoms, but hemophilia A results from factor VIII deficiency while hemophilia B involves factor IX deficiency. Treatment approaches differ accordingly, using specific factor concentrates.

Can gene therapy cure hemophilia A?

Gene therapy shows great promise, with several trials demonstrating sustained factor VIII production. While not yet widely available, these treatments may offer functional cures for many patients in the coming years.

What should I do if my child is bleeding and factor concentrate isn’t immediately available?

Apply direct pressure to external bleeding, immobilize injured joints, and seek emergency medical care immediately. Emergency departments can provide fresh frozen plasma or other temporary measures while arranging factor concentrate access.

Support and resources

The World Federation of Hemophilia (https://wfh.org) provides global advocacy and educational resources. The National Hemophilia Foundation (https://hemophilia.org) offers comprehensive patient education and support programs. Orphanet (https://orpha.net) maintains detailed information about hemophilia A and research updates.

EURORDIS (https://eurordis.org) advocates for rare disease patients across Europe, while the National Organization for Rare Disorders (https://rarediseases.org) provides similar support in North America. Local hemophilia societies offer peer support, educational programs, and assistance accessing treatments.

Related conditions

Hemophilia B results from factor IX deficiency and presents similarly to hemophilia A. Von Willebrand disease is the most common inherited bleeding disorder, affecting both males and females. Factor XI deficiency causes mild to moderate bleeding symptoms. Glanzmann thrombasthenia is a rare platelet function disorder causing severe bleeding. Bernard-Soulier syndrome involves platelet adhesion defects leading to bleeding complications.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, UpToDate, relevant EULAR/ACR/WHO guidelines. This article is for informational purposes only and does not constitute medical advice. Content licensed under CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.